Total Payments
$380,237
2024 Payments
$6,115
Companies
22
Transactions
313
Medicare Patients
106
Medicare Billing
$9,362
Payment Breakdown by Category
Consulting$172,368 (45.3%)
Other$129,472 (34.1%)
Travel$40,386 (10.6%)
Research$29,444 (7.7%)
Food & Beverage$8,566 (2.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $172,368 | 48 | 45.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $129,472 | 53 | 34.1% |
| Travel and Lodging | $40,386 | 77 | 10.6% |
| Unspecified | $29,444 | 7 | 7.7% |
| Food and Beverage | $8,566 | 128 | 2.3% |
Payments by Type
General
$350,792
306 transactions
Research
$29,444
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $133,976 | 117 | $0 (2024) |
| Genentech USA, Inc. | $112,914 | 103 | $0 (2021) |
| F. Hoffmann-La Roche AG | $59,291 | 34 | $0 (2023) |
| Eli Lilly and Company | $22,756 | 3 | $0 (2021) |
| Boehringer Ingelheim International GmbH | $12,160 | 9 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $9,400 | 8 | $0 (2024) |
| United Therapeutics Corporation | $5,971 | 4 | $0 (2022) |
| Esperion Therapeutics, Inc. | $5,700 | 2 | $0 (2022) |
| Actelion Pharmaceuticals, Ltd | $4,500 | 1 | $0 (2019) |
| ABBVIE INC. | $4,025 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,115 | 5 | ABBVIE INC. ($4,025) |
| 2023 | $12,783 | 14 | Boehringer Ingelheim Pharmaceuticals, Inc. ($8,516) |
| 2022 | $9,823 | 12 | Esperion Therapeutics, Inc. ($5,700) |
| 2021 | $19,644 | 13 | United Therapeutics Corporation ($5,859) |
| 2020 | $43,321 | 17 | Eli Lilly and Company ($22,707) |
| 2019 | $80,742 | 64 | Boehringer Ingelheim Pharmaceuticals, Inc. ($48,476) |
| 2018 | $117,396 | 116 | Genentech USA, Inc. ($59,590) |
| 2017 | $90,414 | 72 | Boehringer Ingelheim Pharmaceuticals, Inc. ($31,019) |
All Payment Transactions
313 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/14/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $134.49 | General |
| Category: RESPIRATORY | ||||||
| 10/14/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $43.32 | General |
| Category: RESPIRATORY | ||||||
| 10/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $161.73 | General |
| 05/17/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $4,025.00 | General |
| 01/05/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| 10/10/2023 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $75.50 | General |
| Category: Inflammation | ||||||
| 10/09/2023 | Genentech, Inc. | Esbriet (Biological) | Food and Beverage | In-kind items and services | $153.27 | General |
| Category: Immunology | ||||||
| 10/09/2023 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $37.67 | General |
| Category: Inflammation | ||||||
| 10/08/2023 | Genentech, Inc. | Esbriet (Biological) | Food and Beverage | In-kind items and services | $102.12 | General |
| Category: Immunology | ||||||
| 10/08/2023 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $7.58 | General |
| Category: Inflammation | ||||||
| 07/14/2023 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $20.73 | General |
| Category: Inflammation | ||||||
| 06/30/2023 | F. Hoffmann-La Roche AG | Esbriet (Biological) | — | In-kind items and services | $764.27 | Research |
| Study: An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies • Category: Immunology | ||||||
| 06/28/2023 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $14.74 | General |
| Category: Inflammation | ||||||
| 05/30/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $101.42 | General |
| Category: RESPIRATORY | ||||||
| 03/31/2023 | F. Hoffmann-La Roche AG | Esbriet (Biological) | — | In-kind items and services | $3,065.55 | Research |
| Study: An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies • Category: Immunology | ||||||
| 03/14/2023 | PTC Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $25.16 | General |
| 01/03/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Consulting Fee | Cash or cash equivalent | $8,240.00 | General |
| Category: RESPIRATORY | ||||||
| 01/03/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $140.00 | General |
| Category: RESPIRATORY | ||||||
| 01/03/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: RESPIRATORY | ||||||
| 12/16/2022 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 12/09/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $918.29 | General |
| Category: RESPIRATORY | ||||||
| 12/09/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $207.19 | General |
| Category: RESPIRATORY | ||||||
| 12/09/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $39.51 | General |
| Category: RESPIRATORY | ||||||
| 11/28/2022 | Esperion Therapeutics, Inc. | NEXLETOL (Drug), NEXLIZET | Consulting Fee | Cash or cash equivalent | $2,850.00 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/17/2022 | Genentech, Inc. | Esbriet (Biological) | Food and Beverage | In-kind items and services | $19.47 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | Eli Lilly and Company | $22,756 | 3 |
| An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies | F. Hoffmann-La Roche AG | $3,830 | 2 |
| A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS | F. Hoffmann-La Roche AG | $2,746 | 1 |
| A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | United Therapeutics Corporation | $112.63 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 1 | 13 | 13 | $2,870 | $820.98 |
| 2021 | 5 | 79 | 107 | $22,821 | $7,485 |
| 2020 | 1 | 14 | 16 | $1,600 | $1,056 |
Total Patients
106
Total Services
136
Medicare Billing
$9,362
Procedure Codes
7
All Medicare Procedures & Services
7 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 13 | 13 | $2,870 | $820.98 | 28.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 23 | 43 | $11,438 | $3,499 | 30.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 19 | 23 | $4,255 | $1,302 | 30.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 12 | 12 | $4,212 | $1,286 | 30.5% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 12 | 13 | $1,300 | $912.86 | 70.2% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 13 | 16 | $1,616 | $484.32 | 30.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 14 | 16 | $1,600 | $1,056 | 66.0% |
About Dr. Marilyn Glassberg, MD
Dr. Marilyn Glassberg, MD is a Pulmonary Disease healthcare provider based in Maywood, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1033146782.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Marilyn Glassberg, MD has received a total of $380,237 in payments from pharmaceutical and medical device companies, with $6,115 received in 2024. These payments were reported across 313 transactions from 22 companies. The most common payment nature is "Consulting Fee" ($172,368).
As a Medicare-enrolled provider, Glassberg has provided services to 106 Medicare beneficiaries, totaling 136 services with total Medicare billing of $9,362. Data is available for 3 years (2020–2022), covering 7 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Pulmonary Disease
- Location Maywood, IL
- Active Since 06/27/2006
- Last Updated 08/09/2022
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1033146782
Products in Payments
- OFEV (Drug) $92,652
- Esbriet (Biological) $83,882
- Non-Covered Product (Drug) $9,638
- NEXLETOL (Drug) $5,700
- TYVASO (Drug) $211.19
- Xolair (Biological) $189.59
- TAVNEOS (Drug) $156.22
- Inspire Upper Airway Stimulation System (Device) $116.86
- LONHALA MAGNAIR (Drug) $65.23
- XARELTO (Drug) $53.53
- AMBISOME (Drug) $20.63
- Monarch (Device) $17.69
- Arikayce (Drug) $15.53
- SMARTVEST (Device) $10.92
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Maywood
Daniel Dilling, Md, MD
Pulmonary Disease — Payments: $235,997
Pulmonary Disease $235,997
Dr. Matthew Nobari, Md, MD
Pulmonary Disease — Payments: $204,781
Pulmonary Disease $204,781
James Gagermeier, Md, MD
Pulmonary Disease — Payments: $15,923
Pulmonary Disease $15,923
Daniel Djondo, M.d, M.D
Pulmonary Disease — Payments: $4,240
Pulmonary Disease $4,240
Sana Quddus, M.d, M.D
Pulmonary Disease — Payments: $1,181
Pulmonary Disease $1,181
Ciaran Cunningham, Md, MD
Pulmonary Disease — Payments: $877.41
Pulmonary Disease $877.41